The client began as a contract sales organization serving large pharmaceutical companies. Market dynamics had been deteriorating as the pharmaceutical industry as a whole began to reduce the size of its sales force and as large customers started negotiating more aggressively.

A leading pharmacy benefit management (PBM) company had achieved a robust growth trajectory via organic growth and acquisitions. Health Business Group was asked to evaluate the attractiveness of other medical benefits markets including oncology, radiology, orthopedics, and medical devices and to develop an entry strategy for the more promising ones.

A large private equity firm asked Health Business Group to assist in the commercial due diligence of a core information technology provider for health plans.The target was a leading player with smaller health plans and was aggressively trying to gain ground with larger customers but encountering entrenched competitors.

A client with cutting-edge technology for point-of-care clinical decision support for providers was pursuing opportunities to expand into the adjacent payer and pharmaceutical markets.Expansion into new markets meant a whole new set of direct and indirect competitors.

Health Business Group has assisted many clients in developing their growth strategies, often tapping into new products and services in existing customer segments and assisting clients in expanding into new customer segments.

A leading medical technology company asked Health Business Group to evaluate whether the company should expand its presence in the market for remote patient monitoring (RPM) for chronic illness. RPM is a promising technology that has the potential to address fundamental issues in healthcare, especially the rising demand for chronic care coupled with caregiver shortages and financial constraints.

Passage of the Affordable Care Act (ACA) has created attractive opportunities for private equity firms to invest in companies that serve newly insured segments of the population and contain costs. But investing in the sector requires insight into the details of how health reform is rolling out and how different players in the market are likely to react to new incentives, rules and opportunities.